Showing 41 - 60 results of 201 for search '"hematopoietic stem cell transplantation"', query time: 0.08s Refine Results
  1. 41

    Early Pathologic Findings of Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation: A Proposal from a Case by Rie Nakamoto-Matsubara, Hidekazu Nishikii, Kenji Yamada, Masafumi Ito, Yuichi Hasegawa, Naoki Kurita, Naoshi Obara, Yasushi Okoshi, Kazumi Suzukawa, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Masayuki Noguchi, Shigeru Chiba

    Published 2012-01-01
    “…Bronchiolitis obliterans (BO) is one of the serious, noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early diagnosis of BO is usually difficult because patients are often asymptomatic at an initial stage of the disease and pathologic findings are available mostly at the late stages. …”
    Get full text
    Article
  2. 42
  3. 43
  4. 44

    DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation by B. Dhakal, A. D’Souza, M. Pasquini, W. Saber, T. S. Fenske, R. B. Moss, W. R. Drobyski, P. Hari, M. Z. Abidi

    Published 2016-01-01
    “…Parainfluenza virus (PIV) may cause life-threatening pneumonia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Currently, there are no proven effective therapies. …”
    Get full text
    Article
  5. 45

    Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants by Santiago Grau, Carlos Solano, Carol García-Vidal, Isidro Jarque, Jon A. Barrueta, Carmen Peral, Irene Rodríguez, Darío Rubio-Rodríguez, Carlos Rubio-Terrés

    Published 2015-10-01
    “…**Objectives:** Compare the cost of the primary prophylaxis of invasive fungal infections (IFI) with voriconazole, posaconazole, and micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in hospitals of the National Health System (NHS) in Spain. …”
    Get full text
    Article
  6. 46

    Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation by Yao-Chung Liu, Sheng-Hsuan Chien, Nai-Wen Fan, Ming-Hung Hu, Jyh-Pyng Gau, Chia-Jen Liu, Yuan-Bin Yu, Liang-Tsai Hsiao, Tzeon-Jye Chiou, Cheng-Hwai Tzeng, Po-Min Chen, Jin-Hwang Liu

    Published 2016-01-01
    “…The cure of hematologic disorders by allogeneic hematopoietic stem cell transplantation (HSCT) is often associated with major complications resulting in poor outcome, including graft-versus-host disease (GVHD), relapse, and death. …”
    Get full text
    Article
  7. 47
  8. 48
  9. 49
  10. 50

    Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial by Annoek E. C. Broers, Ellen Meijer, Bronno van der Holt, Cornelis N. de Jong, Erfan Nur, Geerte L. van Sluis, Goda Choi, Michel van Gelder, Johan A. Maertens, Jürgen Kuball, Dries Deeren, Heleen A. Visser‐Wisselaar, Lamberdina A. H. M. Meulendijks, Jan J. Cornelissen, the HOVON Stem Cell Transplantation Working Group

    Published 2024-12-01
    “…Abstract Cyclosporine A combined with mycophenolate mofetil (CsA/MMF) has become an established regimen for the prevention of graft‐versus‐host disease (GVHD) following non‐myeloablative (NMA) allogeneic hematopoietic stem cell transplantation (alloHSCT). However, the optimal duration of immunosuppression (IS) has not yet been defined and overtreatment is of concern. …”
    Get full text
    Article
  11. 51
  12. 52
  13. 53
  14. 54

    A 54-Year-Old Woman with Donor Cell Origin of Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of CML by Erika Maestas, Shikha Jain, Patrick Stiff

    Published 2016-01-01
    “…Chronic myeloid leukemia is a myeloproliferative disorder that may be treated with hematopoietic stem cell transplantation (HSCT). While posttransplantation relapse of disease resulting from a failure to eradicate the patient’s original leukemia could occur, patients may also rarely develop a secondary malignancy or myelodysplastic syndrome (MDS) of donor origin termed donor cell leukemia (DCL). …”
    Get full text
    Article
  15. 55

    Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas by Luis F. Porrata, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Stephen M. Ansell, William J. Hogan, Svetomir N. Markovic

    Published 2010-01-01
    “…Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). …”
    Get full text
    Article
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60